THR-β Modulating Oxindoles for Selective Liver Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) lack effective methods to halt progression and reverse fibrosis, which is a major predictor of liver disease evolution, and existing thyroid hormone receptor (THR) modulators have limitations in selectivity and cardiac side effects.
Innovation Solution
Development of specific THR-β modulating compounds, such as those described in Formulas I, I′, and IA, which are designed to selectively target the liver while minimizing cardiac effects, using structural modifications to achieve therapeutic selectivity and efficacy in treating NAFLD and NASH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing THR modulators are used to treat NAFLD and NASH, then lipid lowering effect is achieved, but cardiac side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (indoline core with particular substituent patterns at positions 3, 4, and 5) that confer selective affinity for THR-β over THR-α. This structural differentiation enables the compound to preferentially act on liver THR-β receptors while minimizing interaction with cardiac THR-α receptors, thereby achieving local therapeutic effect in the liver while sparing the heart from side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including substituent types (halogens, alkyl groups, alkoxy groups), their positions on the indoline ring system, and stereochemistry. These parameter modifications are optimized to enhance THR-β binding affinity while reducing THR-α affinity, thus improving the therapeutic index by changing the selectivity parameters of the compound
2Reliability
If THR agonists are designed with high structural similarity between ligand-binding domains for TRβ and TRα, then binding affinity is achieved, but selectivity is reduced
Solution Approach 1:
The patent applies asymmetry by introducing chiral centers in the indoline structure (particularly at the 2-position with various R6 substituents) and using asymmetric substitution patterns on the aromatic rings. This asymmetric molecular architecture creates diastereomers and enantiomers with different spatial configurations that can differentiate between the binding pockets of THR-β and THR-α, enabling selective binding despite overall structural similarity between the two receptor ligand-binding domains
Solution Approach 2:
The patent segments the molecule into distinct functional regions: a core indoline structure providing basic THR binding, aromatic substituents (R1-R5) providing selectivity control, and specific stereochemical elements (R6-R11) fine-tuning receptor preference. This segmentation allows independent optimization of each region to achieve both high affinity and selectivity
Data Source
AI summary
Disclosed herein are compounds of Formula I′:or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.